ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
UK patients with rare blood disorders receive new treatment option
May 21, 2021NICE has recommended that Ultomiris (ravulizumab) be available on the NHS for patients with paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome. -
NHS patients with rare blood disorders gain access to Ultomiris
May 21, 2021NHS patients with paroxysmal nocturnal haemoglobinuria (PNH) or atypical haemolytic uraemic syndrome (aHUS) are to get access to treatment with Alexion's Ultomiris (ravulizumab) following a green light from cost regulators.
Pharma Sources Insight January 2025
